5-Fluorouracil and levamisole exacerbate demyelination in susceptible mice infected with Theiler's virus

Experimental Neurology

Volumn 147, Issue 1, 1997, Pages 123-129

  Lucchinetti, C F ^a   Kimmel, D W ^a   Pavelko, K ^b   Rodriguez, M ^a,b  

^a MAYO CLINIC   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; IMMUNOMODULATING AGENT; LEVAMISOLE; PYRIMIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN INFECTION; COLON CANCER; CONTROLLED STUDY; DEMYELINATING DISEASE; DISEASE PREDISPOSITION; DRUG EFFECT; DRUG MIXTURE; DRUG SCREENING; EXPERIMENTAL MODEL; MOUSE; MULTIPLE SCLEROSIS; MURINE ENCEPHALOMYELITIS VIRUS; NONHUMAN; PRIORITY JOURNAL; VIRUS INFECTION;

EID: 0031238898     PISSN: 00144886     EISSN: None     Source Type: Journal    
DOI: 10.1006/exnr.1997.6598     Document Type: Article

References (32)

1. Cendrowski W., Cztonkowska A. Levamisole in multiple sclerosis with special reference to immunological parameters. Acta Neurol. Scand. 57:1978;354-359.
2. Chen T. C., Hintom D. R., Leichman. Multifocal inflammatory leukoencephalopathy with levamisole and 5-fluorouracil: Case report. Neurosurgery. 35:1994;1138-1143.
3. Connolly K. M., Diasio R. B., Armstrong D. R., Kaplan A. M. Decreased immunosuppression associated with 5-deoxy-5-fluorouridine compared to 5-fluorouracil and 5-fluorouradine. Cancer Res. 43:1983;2529-2535.
4. Dau P. C., Johnson K. P., Spitler L. E. The effect of levamisole on cellular immunity in multiple sclerosis. Clin. Exp. Immunol. 26:1976;302-309.
5. Fassas A. B. T., Gattani A., Morgello S. Cerebral demyelination with 5-fluorouracil and levamisole. Cancer Invest. 12:1994;379-383.
6. Gonsette R. E., Demonty L., Delmotte P. Modulation of immunity in multiple sclerosis. A double blind levamisole placebo-controlled study in 85 patients. J. Neurol. 228:1982;65-72.
7. Gudvangen R. J., Duffy P. S., Paque R. E., Gauntt. Levamisole exacerbates Coxsackievirus B3-induced murine myocarditis. Infect. Immun. 41:1983;1157-1165.
8. Hadden J. W., Delmonte L., Oettgen H. F. Mechanism of immunopotentiation. Immunopathology. 1977;Plenum, New York. p. 279-313.
9. Hook C. C., Kimmel D. W., Kvols L. K. Multifocal inflammatory leukoencephalopathy with 5-fluorouracil and levamisole. Ann. Neurol. 31:1992;262-267.
10. Kimmel D. W., Schutt A. J. Multifocal leukoencephalopathy occurring during 5-fluorouracil and levamisole therapy and resolution after discontinuation of chemotherapy. Mayo Clin. Proc. 68:1993;363-365.
11. Kimmel D. W., Wijdicks E. F., Rodriguez M. Multifocal leukoencephalopathy associated with levamisole therapy. Neurology. 45:1995;374-376.
12. Koenig H., Patel A. Biochemical basis for fluorouracil neurotoxicity: The role of Krebs cycle inhibition by fluoro-acetate. Arch. Neurol. 23:1970;155-160.
13. Lampert P. W., Rodriguz M. Virus-induced demyelination. Notkins A. L. Concepts in Viral Pathogenesis. 1984;260-268 Springer-Verlag, New York.
14. B. W. Langley, 1973, Blood Levels with 1-Tetramisole.
15. Leichman L., Brown T., Poplin B. Symptomatic, radiologic, and pathologic changes in the central nervous system associated with 5-fluorouracil (5-FU) and levamisole (LE) therapy. Proc. Am. Soc. Clin. Oncol. 12:1993;198.
16. Lucia P., Pocek M., Passacantando A., Sebastiani M. L., Martinis C. Multifocal leukoencephalopathy induced by levamisole. Lancet. 348:1996;1450.
17. Mertin J., Knight S. C., Rudge P. Double-blind controlled trial of immunosuppression in treatment of multiple sclerosis. Lancet. 2:1980;949-951.
18. Moertel C. G., Fleming T. R., MacDonald J. S. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N. Engl. J. Med. 322:1990;352-359.
19. Neur I. S., Ober H. Multifocal inflammatory leukoencephalopathy caused by adjuvant therapy with 5-fluorouracil and levamisole after resection for adenocarcinoma of the colon (letter). Acta Neurol. Scand. 87:1993;70.
20. Neur I. S., Ober H. Multifocal leukoencephalopathy following adjuvant therapy with 5-fluorouracil and levamisole (letter). Dtsch. Med. Wochenschr. 117:1992;1379.
21. Okeda R., Kara Kama T., Kimura S. Neuropathologic study on 5-fluorouracil and its masked compounds in dogs. Acta Neuropathol. 63:1984;334-343.
22. Patick A. K., Lindsley M. D., Rodriguez M. Differential pathogenesis between mouse strains resistant and susceptible to Theiler's virus-induced demyelination. Semin. Virol. 1:1990;281-288.
23. Pinedo H. M., Peters G. F. Fluorouracil biochemistry and pharmacology. J. Clin. Oncol. 9:1988;2052-2066.
24. Riehl J. L., Brown W. J. Acute cerebellar syndrome secondary to 5-fluorouracil therapy. Arch. Neurol. 14:1970;961-967.
25. Rodriguez M., Leibowitz J., David C. S. Susceptibility to Theiler's virus-induced demyelination. Mapping of the gene within the H-2D region. J. Exp. Med. 163:1986;620-631.
26. M. Rodriguez, E. Olesck, J. Leibowitz, Theiler's murine encephalomyelitis virus. A model of demyelination and virus persistence, CRC Crit. Rev. Immunol. 7, 325, 366.
27. Rodriguez M., Pavelko K. D., Njenga M. K., Logan W. C., Wettstein P. J. The balance between persistent virus infection and immune cells determines demyelination. J. Immunol. 157:1996;5699-5708.
28. Rodriguez M., David C. D. H-2d transgene suppresses Theiler's virus-induced demyelination in susceptible strains of mice. J. Neurovirol. 1:1995;111-117.
29. Rodriguez M., Sriram S. Successful therapy of Theiler's virus-induced demyelination (DA strain) with monoclonal anti-lyt-2 antibody. J. Immunol. 140:1988;2950-2955.
30. Silverberg E., Boring C. C., Squires T. S. Cancer Statistics. 40:1990;9-26.
31. Stevenson H. C., Green I., Hamilton J. M., Calabro B. A., Parkinson D. R. Levamisole: Known effects on the immune system, clinical results, and future applications to the treatment of cancer. J. Clin. Oncol. 9:1991;2052-2066.
32. Vanevelde M., Boring J. G., Hoff E. J., Gingerich D. A. The effect of levamisole on the canine central nervous system. J. Neuropathol. Exp. Neurol. 37:1978;163-173.